New study tracks how ILARIS works in everyday care for rare inflammatory diseases
NCT ID NCT07517250
First seen Apr 12, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This study looks at how patients with Familial Mediterranean Fever (FMF) or Still's disease (including juvenile and adult forms) are treated with the drug canakinumab (ILARIS) in real-world clinics across Europe and Israel. Researchers will track 160 people who have been on the drug for at least 6 months to see how well it controls their disease and whether they can reduce other medications like steroids. The goal is to better understand long-term outcomes and treatment patterns outside of a controlled trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis
RECRUITINGBasel, CH-4056, Switzerland
Conditions
Explore the condition pages connected to this study.